Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Influenza01:27

Influenza

Influenza is an acute, highly communicable viral disease that affects the respiratory tract and is responsible for seasonal epidemics worldwide. Influenza A is the most prevalent type associated with widespread outbreaks and is subtyped based on two surface glycoproteins: hemagglutinin (H) and neuraminidase (N), as in H1N1. These glycoproteins are essential for viral infectivity, transmission, and immune recognition. Transmission occurs primarily through respiratory droplets and contaminated...
Infectious Diseases and Their Occurrence01:28

Infectious Diseases and Their Occurrence

Infectious diseases appear in populations through various transmission patterns, influenced by pathogen characteristics, population immunity, environmental conditions, and social behavior. Understanding these patterns is essential for effective public health surveillance and intervention. These categories—sporadic, outbreak, epidemic, pandemic, and endemic—help frame the nature and scope of disease events.Sporadic diseases occur irregularly and infrequently, without a predictable temporal or...
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the Hospital Burden Associated with Respiratory Syncytial Virus and Human Metapneumovirus Across All Age Groups in Scotland: A Retrospective Analysis.

Infectious diseases and therapy·2026
Same author

Viral Pathogen-Specific Severe Acute Respiratory Infections in Hospitalised Adults in Europe: Epidemiological Findings from the id.DRIVE Study 2024-2025.

Infectious diseases and therapy·2026
Same author

Effect of Recruitment Video Presenter Sex on Trial Enrollment.

JAMA·2026
Same author

Hospitalization Burden Estimates of Respiratory Syncytial Virus With Adjustment for Case Underascertainment in Adults Aged 18 to 65 Years in High-Income Countries: A Systematic Review, Meta-Analysis, and Modeling Study.

Open forum infectious diseases·2026
Same author

Effect of RSV Vaccine in Older Adults with Atrial Fibrillation: A Prespecified Analysis of the DAN-RSV Trial.

European journal of preventive cardiology·2026
Same author

Corrigendum to "Impact of simultaneous administration on immune responses to vaccines routinely recommended for use during pregnancy: A targeted literature review" [Vaccine 79 (2026) 128408].

Vaccine·2026

Related Experiment Video

Updated: Jul 12, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

Country-Level RSV-Related Hospitalisation Rates Among Adults in High-Income Countries From an Ensemble Model Based on

Shuyu Deng1,2, Tiantian Zhang1,2, Yihua Xu1,2

  • 1Department of Epidemiology, National Vaccine Innovation Platform, School of Public Health, Nanjing Medical University, Nanjing, China.

Influenza and Other Respiratory Viruses
|July 9, 2026
PubMed
Summary

This study estimates respiratory syncytial virus (RSV)-associated acute respiratory infection (ARI) hospitalizations in adults across 63 high-income countries. Findings provide crucial data for informing RSV immunisation policies where primary data are lacking.

Keywords:
adultdisease burdenhospitalisationpredictionrespiratory syncytial virusunderascertainmentvaccine

More Related Videos

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Related Experiment Videos

Last Updated: Jul 12, 2026

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
09:01

An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection

Published on: December 10, 2013

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Area of Science:

  • Epidemiology
  • Infectious Diseases
  • Public Health

Background:

  • Respiratory syncytial virus (RSV) causes significant acute respiratory infection (ARI) hospitalizations in adults.
  • Data on RSV burden in adults are lacking in many high-income countries, hindering informed immunisation policy.
  • Estimating RSV-associated ARI hospitalisation rates is crucial for public health planning.

Purpose of the Study:

  • To estimate country-level RSV-associated ARI hospitalisation rates in adults aged 18-64 and ≥65 years.
  • To provide data for high-income countries lacking primary RSV burden information.
  • To inform the development of RSV immunisation policies.

Main Methods:

  • Systematic literature review and national surveillance reports were used to gather data on adult RSV hospitalisations.
  • Bayesian adjustment was applied to account for underascertainment in diagnostic methods and clinical specimens.
  • An ensemble modelling framework with four independent approaches predicted country-level RSV-associated ARI hospitalisation rates across 63 high-income countries.

Main Results:

  • The ensemble model predicted median annual RSV-associated ARI hospitalisation rates of 39/100,000 for adults 18-64 years and 374/100,000 for adults ≥65 years.
  • Significant continental variations were observed, with the Americas showing the highest rates in older adults (455/100,000) and Oceania in younger adults (50/100,000).
  • Africa (Seychelles) reported the lowest rates (17/100,000 for 18-64 years; 188/100,000 for ≥65 years), while Europe and Asia exhibited considerable within-continent variability.

Conclusions:

  • This study provides a valuable alternative reference for high-income countries lacking primary RSV disease burden data.
  • The findings are essential for evidence-based development of RSV vaccine policies.
  • Accurate estimation of RSV burden is critical for effective public health interventions and resource allocation.